Suchergebnisse - "Tobinai, K"

PubPharm (202)

1

The ECHELON-2 Trial : 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2022

von Horwitz, S. | O'Connor, O. | Pro, B. | +27

2

Tirabrutinib hydrochloride for B-cell lymphomas

enthalten in: Drugs of today (Barcelona, Spain : 1998) | 2021

von Munakata, W. | Tobinai, K.

3

Tirabrutinib hydrochloride for B-cell lymphomas

enthalten in: Drugs of today | 2021

von Munakata, W. | Tobinai, K.

4

A PHASE 2B OPEN‐LABEL SINGLE ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF HBI‐8000 (TUCIDINOSTAT) IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T‐CELL LYMPHOMA (PTCL)

enthalten in: Hematological Oncology | 2021

von Kim, W. | Rai, S. | Ando, K. | +28

5

A PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TUCIDINOSTAT (HBI‐8000) IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY ADULT T‐CELL LEUKEMIA‐LYMPHOMA (ATL)

enthalten in: Hematological Oncology | 2021

von Izutsu, K. | Utsunomiya, A. | Jo, T. | +21

6

FIRST‐IN‐HUMAN STUDY OF THE EZH1 AND EZH2 DUAL INHIBITOR VALEMETOSTAT TOSYLATE (DS‐3201B) IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMAS

enthalten in: Hematological Oncology | 2021

von Ishitsuka, K. | Izutsu, K. | Maruyama, D. | +18

7

Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma

in: OncoTargets and Therapy | 2020

von Makita S | Maruyama D | Tobinai K

8

ANALYSIS OF PUBLISHED TREATMENT OPTIONS FOR RELAPSED OR REFRACTORY (R/R) PERIPHERAL T–CELL LYMPHOMA (PTCL) : AN EVIDENCE BASED DECISION MAKING APPROACH

enthalten in: Hematological Oncology | 2019

von Marchi, E. | Tobinai, K. | Maruyama, D. | +2

9

Antibody therapy targeting CD19 for B-cell non-Hodgkin's lymphoma

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2018

von Makita, S. | Tobinai, K.

CommentOn: Ann Oncol. 2018 May 1;29(5):1266-1272. - PMID 29444231

10

Adjuvant everolimus in high-risk diffuse large B-cell lymphoma : final results from the PILLAR-2 randomized phase III trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2018

von Witzig, T. | Tobinai, K. | Rigacci, L. | +22

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[21]